BMI1 and cancer: Though the direct role of BMI1+ NB-CSCs in orchestrating therapy resistance is currently unknown, targeting BMI1+ CSCs has been shown to overcome chemoresistance[122-125] and radio-resistance[126-128] in many human cancers.